Skip to main content
I

IMMUTEP LIMITED — Investor Relations & Filings

Ticker · IMM ISIN · AU000000IMM6 LEI · 529900OL6C5CY5P8BH38 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,777 across all filing types
Latest filing 2026-04-26 Major Shareholding Noti…
Country AU Australia
Listing ASX IMM

About IMMUTEP LIMITED

https://www.immutep.com

Immutep Limited focuses on the development of novel immunotherapy treatments for cancer and autoimmune diseases, specifically targeting the Lymphocyte Activation Gene-3 (LAG-3) pathway. The company's lead therapeutic candidate is eftilagimod alpha (efti), a first-in-class soluble LAG-3 protein and MHC class II agonist. Efti functions by activating antigen-presenting cells, which in turn triggers a robust T cell response against tumors. It is currently being evaluated in clinical trials for multiple solid tumor indications, including non-small cell lung cancer and head and neck squamous cell carcinoma, frequently in combination with other anti-cancer agents. The pipeline also includes IMP761, an agonist antibody designed to suppress overactive immune responses in autoimmune conditions. The company's technology utilizes the LAG-3 protein's role in immune regulation to create targeted therapeutic interventions.

Recent filings

Filing Released Lang Actions
Change in substantial holding 32 pages 1.8MB
Major Shareholding Notification Classification · 1% confidence The document is an Australian Form 604 under the Corporations Act 2001 (Section 671B) titled “Notice of change of interests of substantial holder,” detailing changes in voting power and relevant interests of JPMorgan Chase & Co. and its affiliates. This is a notification of changes in significant share ownership levels by a substantial holder. Therefore, it aligns with Major Shareholding Notification (Code: MRQ).
2026-04-26 English
Change in substantial holding 6 pages 355.3KB
Major Shareholding Notification Classification · 1% confidence The document is an Australian Corporations Act Form 604 ‘‘Notice of Change of Interests of Substantial Holder.’’ It details the previous and present voting power, changes in relevant interests, and associations of a substantial shareholder (BNY) in Immutep Limited. This clearly falls under a major shareholding notification rather than an earnings release, proxy statement, or other category.
2026-04-26 English
Change in substantial holding 22 pages 1.0MB
Major Shareholding Notification Classification · 1% confidence The document is a Form 604 filed under the Australian Corporations Act 2001, titled “Notice of change of interests of substantial holder.” It details changes in voting power and relevant interests of JPMorgan Chase & Co. and affiliates, including tables of shareholdings and trades. This is a notification of significant share ownership changes, matching the “Major Shareholding Notification” category.
2026-04-22 English
Abstract on Efti accepted for presentation at ASCO 2026 2 pages 137.0KB
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing that an abstract has been accepted for presentation at a clinical conference (ASCO 2026). It contains no financial results, no management changes, no dividend or share transactions, and is not a formal report itself. It does not match any specific report category (e.g., earnings release, annual/interim report, governance, M&A, etc.). Therefore it falls into the fallback category for miscellaneous regulatory announcements.
2026-04-21 English
Change in substantial holding 19 pages 1.2MB
Major Shareholding Notification Classification · 1% confidence The document is a "Form 604 – Notice of change of interests of substantial holder" filed under the Corporations Act 2001. It provides detailed disclosures of shareholding thresholds, voting power, changes in interests, and trades by a substantial shareholder (JPMorgan Chase & Co. and affiliates). This matches the definition of a Major Shareholding Notification rather than a financial report, management change, or dividend notice.
2026-04-16 English
Immutep receives FDA ODD for Efti in Soft Tissue Sarcoma 2 pages 184.5KB
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing FDA Orphan Drug Designation for a clinical‐stage biotechnology company’s product candidate. It is not a financial report (10‐K/IR), earnings release, management discussion, or any of the specific categories (e.g., M&A, delisting, dividend, capital change). It is a regulatory update regarding drug designation, which fits the general “Regulatory Filings” fallback for miscellaneous regulatory announcements (RNS).
2026-04-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.